CUE BIOPHARMA
Cue Biopharma (Cue) is an immunotherapy company developing biologics engineered to selectively modulate disease-relevant T cells for the treatment of cancer and autoimmune disease. Cue biologics generate tailored immune responses in disease-relevant T cell populations by emulating the signals, or cues, delivered by the body’s antigen-presenting cells (APCs), and can potentially address any T cell-mediated disease. Through this platform approach, Cue has developed a portfolio of promising drug ... candidates with two lead programs currently approaching the clinic. Headquartered in Kendall Square, Cambridge, Massachusetts, Cue is led by a strong, experienced management team and scientific advisory board (SAB) with deep expertise in the design and clinical development of protein biologics, immunology, and immuno-oncology.
CUE BIOPHARMA
Industry:
Biopharma Biotechnology Health Care Medical Device
Founded:
2014-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.cuebiopharma.com
Total Employee:
11+
Status:
Active
Contact:
617-949-2680
Total Funding:
26.4 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Font Awesome Nginx
Similar Organizations
ALung Technologies
ALung Technologies develops medical gas exchange devices for the treatment of acute and chronic respiratory disorders.
Asklepios BioPharmaceutical
Asklepios BioPharmaceutical is a biotechnology company developing adeno-associated virus (AAV) gene therapies for genetic disorders.
BioMarck Pharmaceuticals
BioMarck Pharmaceuticals develops new drugs for the treatment of pulmonary diseases.
CN Bio Innovations
CN Bio develops human organ-on-a-chip platforms for the testing and development of therapeutics for serious human diseases.
Fuse Medical
Fuse Medical distributes healthcare products and supplies to ambulatory surgical centers and hospitals.
Kypha
Kypha develops technology and clinical products to improve monitoring and treatment of autoimmune and inflammatory diseases.
NanoBio Designs
NanoBio Designs offers an efficient detection platform to verify the presence or absence and levels of targeted genetic markers in samples.
Sextant Therapeutics
Sextant is developing personalized cancer therapies that trigger the tumor to recruit the patient's own cancer-killing immune response.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Stereotaxis
Stereotaxis develops robotic cardiology instrument navigation systems that enhances the treatment of arrhythmias and coronary diseases.
Theravectys
Theravectys develops a platform for the prevention and treatment of cancers and other infectious diseases and conditions.
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
MDB Capital Group
MDB Capital Group investment in Series B - Cue Biopharma
MDB Capital Group
MDB Capital Group investment in Series A - Cue Biopharma
Key Employee Changes
| Date | New article |
|---|---|
| 2021-12-15 | Cue Biopharma Announces Appointment of Patricia Nasshorn as Chief Business Officer |
Official Site Inspections
http://www.cuebiopharma.com Semrush global rank: 4.72 M Semrush visits lastest month: 2.01 K
- Host name: 157.167.196.104.bc.googleusercontent.com
- IP address: 104.196.167.157
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Cue Biopharma"
About Us - Cue Biopharma
Cue Biopharma Combines Innovation with High Science to Bring a New Class of Immunotherapies to People Affected by Cancer Despite the tremendous promise of immunotherapy for cancer, only a small percentage of patients, estimated …See details»
Cue Biopharma - Crunchbase Company Profile
CUE-101: A clinical candidate designed to activate tumor-specific T cells to target and attack HPV16+ head and neck cancer cells. CUE-102: A biologic that expands the pipeline by targeting different tumor antigens and HLA alleles for …See details»
CueB iopharma, Inc. IMMUNE RESPONSES,ONC UE
Www.cuebiopharma.com CUEBIOPHARMA ANN UA LR EP OR T2 021 ANNUALR EPORT 2021. ... incorporation or organization) (I.R.S. Employer Identification No.) 21 Erie Street Cambridge, …See details»
Cue Biopharma - LinkedIn
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the ...See details»
Cue Biopharma Presents New Positive Data from Ongoing Phase
Nov 10, 2022 All three posters will be available in the Investor & Media section of the Company’s website at www.cuebiopharma.com under ... is a nonprofit organization of medical …See details»
Cue Biopharma, Inc. (CUE) Company Profile & Overview - Stock …
Jan 2, 2018 Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant …See details»
Cue Biopharma Announces Strategic Prioritization of Autoimmune …
Jul 25, 2024 Through strategic realignment and prioritizing autoimmune programs, along with associated organizational restructuring, Cue Biopharma expects to reduce its fiscal year 2025 …See details»
Cue Biopharma - Craft
Oct 18, 2024 Cue Biopharma has 2 employees at their 1 location and $5.49 m in annual revenue in FY 2023. See insights on Cue Biopharma including office locations, competitors, revenue, …See details»
Cue Biopharma - Overview, News & Similar companies - ZoomInfo
Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: …See details»
Cue Biopharma to Present at the 2024 American Society of Clinical ...
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to …See details»
Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen …
BOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to …See details»
Investors & Media - Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within …See details»
Cue lays off 25%, prioritizing preclinical autoimmune assets
Jul 26, 2024 The other drug, CUE-102, is currently in a phase 1 study for patients with late-stage colorectal, gastric/gastroesophageal junction, pancreatic and ovarian cancers that express WT1.See details»
Cue Biopharma Presents Positive Data Update from Ongoing …
May 25, 2023 The poster will be available in the Investor & Media section of the Company’s website at www.cuebiopharma.com under Scientific Publications and Presentations, following …See details»
Cue Biopharma, Inc. (CUE) Stock Price, Quote & News - Stock …
2 days ago Website https://www.cuebiopharma.com. Full Company Profile. Financial Performance. In 2023, Cue Biopharma's revenue was $5.49 million, an increase of 340.96% …See details»
Cue Biopharma, Inc. (CUE) Stock Price, News, Quote & History
Find the latest Cue Biopharma, Inc. (CUE) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Our Approach - Cue Biopharma
Harnessing Nature’s “Cues” to Attack Cancer A crucial breakthrough in the fight against cancer has been the emergence of immunotherapies designed to engage a patient’s immune system. …See details»
News - Cue Biopharma
© 2024 Cue Biopharma. All rights reserved. The name Cue Biopharma, our logo, the tagline "Immune Responses, On Cue," the Cue Biologics name, "Immuno-STAT", "Immuno ...See details»
Product Candidates - Cue Biopharma
CUE-101 CUE-101 is Cue Biopharma’s lead drug product candidate currently being evaluated for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck …See details»